|
On (b)(6) 2023, the following information was reported to kci by the nurse: the activ.A.C.¿ ion progress¿ remote therapy monitoring system that was treating multiple wounds located on the patient's back was removed due to an alleged infection.On (b)(6) 2023, the following information received via clinical records from the physician were reviewed: wound cultures grew proteus and pseudomonas, both sensitive to ciprofloxacin.Based on the strong fruit odor it is suspected the pseudomonas became resistant to ciprofloxacin and is allegedly flourishing under v.A.C.® therapy.The patient was prescribed an oral antibiotic on (b)(6) 2023 and wound care was changed to packing daily.On (b)(6) 2023, the following information was provided to kci by the nurse: v.A.C.® therapy was discontinued due to infection of the wounds.The amount of drainage and the moist environment of the activ.A.C.¿ ion progress¿ remote therapy monitoring system allegedly caused the infection to flourish.The activ.A.C.¿ ion progress¿ remote therapy monitoring system was functioning properly.Wound care was changed to an alternative dressing, and the patient's wounds are improving.On (b)(6) 2023 a device evaluation was completed by kci quality engineering.On (b)(6) 2022, the device was tested per quality control procedure by the kci service center, and the unit passed the quality control checks and met specifications.On (b)(6) 2022, the device was placed with the patient.On (b)(6) 2023, the device was tested per quality control procedure by the kci service center, and the unit passed the quality control checks and met specifications.Inspection and testing of the device did not reveal any evidence of an operational malfunction with the unit.
|
|
Based on the information provided, it cannot be determined that the alleged infection requiring medication is related to the activ.A.C.¿ ion progress¿ remote therapy monitoring system.The patient has a history of wound infections and was on oral antibiotics at the time of activ.A.C.¿ ion progress¿ remote therapy monitoring system placement.The device passed quality control checks before and after patient placement.Device labeling, available in print and online, states: warnings: wound infection: call your doctor or nurse right away if you think your wound is infected or if the following symptoms develop or worsen: you have a fever, your wound is sore, red or swollen, your skin itches or you have a rash or redness around the wound, the area around the wound feels very warm, you have pus or a bad smell coming from the wound.Infected wounds: infected wounds should be monitored closely and may require more frequent dressing changes than noninfected wounds, dependent upon factors such as wound conditions, treatment goals.Refer to dressing application instructions (found in v.A.C.® dressing cartons) for details regarding dressing change frequency.As with any wound treatment, clinicians and patients / caregivers should frequently monitor the patient's wound, periwound tissue and exudate for signs of infection, worsening infection, or other complications.Some signs of infection are fever, tenderness, redness, swelling, itching, rash, increased warmth in the wound or periwound area, purulent discharge or strong odor.Infection can be serious, and can lead to complications such as pain, discomfort, fever, gangrene, toxic shock, septic shock and/or fatal injury.Some signs or complications of systemic infection are nausea, vomiting, diarrhea, headache, dizziness, fainting, sore throat with swelling of the mucus membranes, disorientation, high fever, refractory and/or orthostatic hypotension or erythroderma (a sunburn-like rash).If there are any signs of the onset of systemic infection or advancing infection at the wound site, contact the treating physician immediately to determine if v.A.C.® therapy should be discontinued.Precautions the v.A.C.® therapy system will not be effective in addressing complications associated with the following: ischemia to the incision or incision area, untreated or inadequately treated infection, inadequate hemostasis of the incision, cellulitis of the incision area.Disclaimer: this information is submitted pursuant to 21 cfr 803, in compliance with the medical device reporting requirement and should not be considered to be an admission that a kinetic concepts, inc.Product malfunctioned, is defective or has caused serious injury.
|